UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

Psychedelics and related substances for medical use in the UK are met with cautious guidance from the Royal College of Psychiatrists (RCPsych). RCPsych reviews evidence for psilocybin, LSD, MDMA, and ketamine, including when used alongside psychotherapy, and concludes that high quality evidence for efficacy is currently limited. The guidance flags methodological and clinical uncertainties such as issues with blinding, side effects, and how durable effects are, plus concerns about how well trial results will translate to broader real world patient populations. The College does not recommend routine clinical use except where a product is already licensed, pointing instead to further research needs. It emphasizes studying therapeutic mechanisms and processes, especially the risks such as persistent psychotic and perceptual disorders, and it highlights that therapeutic effects are likely driven by both drug pharmacology and the therapeutic relationship, requiring appropriate training and supervision for the psychological aspects of treatment.